HRP20120696T1 - Spiro-prstenasti spoj i njegova medicinska upotreba - Google Patents
Spiro-prstenasti spoj i njegova medicinska upotreba Download PDFInfo
- Publication number
- HRP20120696T1 HRP20120696T1 HRP20120696AT HRP20120696T HRP20120696T1 HR P20120696 T1 HRP20120696 T1 HR P20120696T1 HR P20120696A T HRP20120696A T HR P20120696AT HR P20120696 T HRP20120696 T HR P20120696T HR P20120696 T1 HRP20120696 T1 HR P20120696T1
- Authority
- HR
- Croatia
- Prior art keywords
- spiro
- solvate
- group
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 4
- 239000012453 solvate Substances 0.000 claims 33
- 150000003413 spiro compounds Chemical class 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 7
- 239000008103 glucose Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 201000001421 hyperglycemia Diseases 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 claims 1
- 229940125827 GPR40 agonist Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/50—Spiro compounds
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (34)
1. Spiro-spoj sljedeće opće formule [Ia]:
[image]
naznačen time što R1 je
(1) atom vodika,
(2) C1-C6 alkilna skupina,
(3) C2-C6 alkenilna skupina,
(4) C2-C6 alkinilna skupina,
(5) C1-C6 alkoksi skupina,
(6) hidroksi C1-C6 alkilna skupina,
(7) C1-C6 alkoksi (C1-C6) alkilna skupina,
(8) -CONR11R12, gdje su R11 i R12 isti ili različiti, a svaki od njih predstavlja atom vodika ili C1-C6 alkilnu skupinu,
(9) fenilna skupina ili
(10) peteročlana heteroarilna skupina, koja ima najmanje jedan heteroatom, kojeg se bira iz skupine koju čine atom dušika, atom kisika i atom sumpora, koja može biti supstituirana s C1-C6 alkilnom skupinom;
R2 je
(1) atom halogena,
(2) C1-C6 alkilna skupina,
(3) hidroksi skupina ili
(4) C1-C6 alkoksi skupina;
p je 0, 1, 2 ili 3;
X je atom ugljika ili atom dušika;
m1 je 0, 1 ili 2;
m2 je 0 ili 1;
spiro-prsten AB može biti supstituiran s 1 do 5 istih ili različitih supstituenata, koje se bira iz skupine koju čine
(1) hidroksi skupina,
(2) C1-C6 alkilna skupina,
(3) C1-C6 alkoksi skupina i
(4) an okso skupina;
n1 je 0, 1, 2, 3 ili 4;
n2 je 1, 2, 3 ili 4;
n3 je 0, 1 ili 2, uz uvjet da n2 + n3 je 2, 3 ili 4; i
gdje veza koju prikazuje simbol:
-----
označuje jednostruku vezu ili dvostruku vezu, uz uvjet da tri uzastopna atoma ugljika ne tvore alensku vezu prikazanu formulom:
C=C=C
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
2. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što spiro-prsten AB prikazuje formula:
[image]
,
gdje je svaki simbol definiran kao u patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
3. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što je broj dvostrukih veza u prstenu A spiro-prstena AB 0 ili 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
4. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što broj dvostrukih veza u prstenu B spiro-prstena AB je 0 ili 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
5. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, wherein n3 je 1 ili 2, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
6. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što spiro-prsten AB prikazuje sljedeća formula:
[image]
[image]
[image]
[image]
[image]
ili
[image]
te gdje spiro-prsten AB može biti supstituiran s 1 do 5 istih ili različitih supstituenata, koje se bira iz skupine koju čine C1-C6 alkilna skupina, hidroksi skupina, okso skupina i C1-C6 alkoksi skupina, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
7. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što spiro-prsten AB može biti supstituiran s 1 do 3 ista ili različita supstituenta, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
8. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7,
naznačen time što R1 je
(1) atom vodika,
(2) C1-C6 alkilna skupina,
(3) C2-C6 alkenilna skupina,
(4) C2-C6 alkinilna skupina,
(5) C1-C6 alkoksi skupina,
(6) C1-C6 alkoksi (C1-C6) alkilna skupina,
(7) -CONR11R12, gdje su R11 i R12 isti ili različiti, a svaki od njih predstavlja atom vodika ili C1-C6 alkilnu skupinu, ili
(8) peteročlana heteroarilna skupina, koja ima najmanje jedan heteroatom, kojeg se bira iz skupine koju čine atom dušika, atom kisika i atom sumpora, koja može biti supstituirana s C1-C6 alkilnom skupinom, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
9. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8,
naznačen time što R1 je
(1) atom vodika,
(2) C2-C6 alkenilna skupina,
(3) C2-C6 alkinilna skupina,
(4) C1-C6 alkoksi skupina ili
(5) peteročlana heteroarilna skupina, koja ima najmanje jedan heteroatom, kojeg se bira iz skupine koju čine atom dušika, atom kisika i atom sumpora, koja može biti supstituirana s C1-C6 alkilnom skupinom, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
10. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što p je 0 ili 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
11. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10,
naznačen time što R2 je
(1) C1-C6 alkilna skupina,
(2) hidroksi skupina ili
(3) C1-C6 alkoksi skupina, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
12. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što m1 je 0 ili 1, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
13. Spiro-spoj u skladu s patentnim zahtjevom 1 sljedeće opće formule [I]:
[image]
naznačen time što R1 je
(1) atom vodika,
(2) C1-C4 alkilna skupina,
(3) C2-C4 alkenilna skupina,
(4) C2-C4 alkinilna skupina,
(5) C1-C4 alkoksi skupina,
(6) hidroksi C1-C4 alkilna skupina,
(7) C1-C4 alkoksi (C1-C4) alkilna skupina,
(8) -CONR11R12, gdje su R11 i R12 isti ili različiti, a svaki od njih predstavlja atom vodika ili C1-C4 alkilnu skupinu,
(9) fenilna skupina ili
(10) peteročlana heteroarilna skupina, koja ima najmanje jedan heteroatom, kojeg se bira između atoma dušika, atoma kisika i atoma sumpora, koja može biti supstituirana s C1-C4 alkilnom skupinom;
m1 je 0, 1 ili 2;
m2 je 0 ili 1;
spiro-prsten AB može biti supstituiran s 1 do 5 istih ili različitih supstituenata, koje se bira između
(1) hidroksi skupine i
(2) C1-C4 alkilne skupine;
n1 je 2, 3 ili 4;
n2 je 1, 2 ili 3;
n3 je 0, 1 ili 2, uz uvjet da n2 + n3 je 2 ili 3;
gdje veza koju prikazuje simbol:
-----
označuje jednostruku vezu ili dvostruku vezu, uz uvjet da tri uzastopna atoma ugljika ne tvore alensku vezu prikazanu formulom:
C=C=C
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
14. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što ga prikazuje jedna od sljedećih formula:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat; ili što ga prikazuje jedna od sljedećih formula:
[image]
ili njegov solvat.
15. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što ga prikazuje sljedeća formula:
[image]
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
16. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što ga prikazuje sljedeća formula:
[image]
ili njegova farmaceutski prihvatljiva sol, ili njegov solvat.
17. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što ga prikazuje sljedeća formula:
[image]
ili njegov solvat
18. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što ga prikazuje sljedeća formula:
[image]
ili njegov solvat.
19. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što ga prikazuje sljedeća formula:
[image]
ili njegov solvat.
20. Spiro-spoj u skladu s patentnim zahtjevom 1, naznačen time što ga prikazuje sljedeća formula:
[image]
ili njegov solvat.
21. Farmaceutski pripravak, naznačen time što sadrži spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat, i farmaceutski prihvatljivu podlogu.
22. GPR40 agonistčki medikament, naznačen time što sadrži spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat, kao djelotvoran sastojak.
23. Sredstvo za poticanje izlučivanje inzulina ili hipoglikemijsko sredstvo, naznačeno time što sadrži spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat, kao djelotvoran sastojak.
24. Farmaceutski pripravak namijenjen upotrebi u liječenju ili sprječavanju bolesti koju se bira iz skupine koju čine dijabetes melitus, hiperglikemija, smanjena tolerancija glukoze i smanjena razina glukoze u gladovanju, naznačen time što sadrži spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegovu farmaceutski prihvatljivu sol, ili njegov solvat, kao djelotvoran sastojak.
25. Upotreba spiro-spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegove farmaceutski prihvatljive soli, ili njegovog solvata, naznačena time što je navedeni spoj namijenjen proizvodnji sredstva za poticanje izlučivanje inzulina ili hipoglikemijskog sredstva.
26. Upotreba spiro-spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegove farmaceutski prihvatljive soli, ili njegovog solvata, naznačena time što je navedeni spoj namijenjen proizvodnji farmaceutskog pripravka za liječenje ili sprječavanje bolesti koju se bira iz skupine koju čine dijabetes melitus, hiperglikemija, smanjena tolerancija glukoze i smanjena razina glukoze u gladovanju.
27. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time što je namijenjen upotrebi kod poticanja izlučivanja inzulina ili smanjivanja razine glukoze u krvi.
28. Spiro-spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti koju se bira iz skupine koju čine dijabetes melitus, hiperglikemija, smanjena tolerancija glukoze i smanjena razina glukoze u gladovanju.
29. Farmaceutski pripravak, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti u skladu s patentnim zahtjevom 24, gdje je bolest dijabetes melitus.
30. Upotreba spiro-spoja, ili njegove farmaceutski prihvatljive soli, ili njegovog solvata, u skladu s patentnim zahtjevom 26, naznačena time što je bolest dijabetes melitus.
31. Spoj, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti u skladu s patentnim zahtjevom 28, gdje je bolest dijabetes melitus.
32. Farmaceutski pripravak, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti u skladu s patentnim zahtjevom 24, gdje je bolest dijabetes melitus tip 2.
33. Upotreba spiro-spoja, ili njegove farmaceutski prihvatljive soli, ili njegovog solvata, u skladu s patentnim zahtjevom 26, naznačena time što je bolest dijabetes melitus tip 2.
34. Spiro-spoj, njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti u skladu s patentnim zahtjevom 28, gdje je bolest dijabetes melitus tip 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007279697 | 2007-10-26 | ||
US182307P | 2007-11-05 | 2007-11-05 | |
PCT/JP2008/069296 WO2009054479A1 (ja) | 2007-10-26 | 2008-10-24 | スピロ環化合物及びその医薬用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120696T1 true HRP20120696T1 (hr) | 2012-10-31 |
Family
ID=40579581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120696AT HRP20120696T1 (hr) | 2007-10-26 | 2012-09-04 | Spiro-prstenasti spoj i njegova medicinska upotreba |
Country Status (30)
Country | Link |
---|---|
US (3) | US8299296B2 (hr) |
EP (3) | EP2684861A3 (hr) |
JP (5) | JP4568779B2 (hr) |
KR (1) | KR101565622B1 (hr) |
CN (1) | CN101835737B (hr) |
AR (1) | AR071055A1 (hr) |
AU (1) | AU2008314933B2 (hr) |
BR (1) | BRPI0818687A2 (hr) |
CA (1) | CA2704013C (hr) |
CL (1) | CL2008003153A1 (hr) |
CO (1) | CO6321230A2 (hr) |
CY (1) | CY1113352T1 (hr) |
DK (1) | DK2202216T3 (hr) |
ES (1) | ES2386596T3 (hr) |
HK (1) | HK1144421A1 (hr) |
HR (1) | HRP20120696T1 (hr) |
IL (1) | IL205283A (hr) |
ME (1) | ME02338B (hr) |
MX (1) | MX2010004435A (hr) |
MY (1) | MY148469A (hr) |
NZ (1) | NZ584161A (hr) |
PE (1) | PE20091014A1 (hr) |
PL (1) | PL2202216T3 (hr) |
PT (1) | PT2202216E (hr) |
RS (1) | RS52474B (hr) |
RU (1) | RU2490250C2 (hr) |
SI (1) | SI2202216T1 (hr) |
TW (1) | TWI421070B (hr) |
WO (1) | WO2009054479A1 (hr) |
ZA (1) | ZA201002305B (hr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101679908B (zh) * | 2007-06-11 | 2012-10-24 | 奇华顿股份有限公司 | 有机化合物 |
EP2684861A3 (en) * | 2007-10-26 | 2014-05-07 | Japan Tobacco Inc. | Spiro compounds and pharmaceutical use thereof |
NZ588983A (en) * | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
SI2448910T1 (sl) * | 2009-06-29 | 2013-07-31 | Merz Pharma Gmbh & Co. Kgaa | Postopek za pripravo nerameksana |
US8759581B2 (en) | 2009-06-29 | 2014-06-24 | Merz Pharma Gmbh & Co. Kgaa | Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane |
EP2448901A1 (en) * | 2009-06-29 | 2012-05-09 | Merz Pharma GmbH & Co. KGaA | Method of preparing 3,3,5,5-tetramethylcyclohexanone |
EP2289881A1 (de) | 2009-08-06 | 2011-03-02 | Boehringer Ingelheim International GmbH | Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen |
AR078522A1 (es) * | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
AR078948A1 (es) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
EA201290574A1 (ru) | 2009-12-25 | 2012-12-28 | Мотида Фармасьютикал Ко., Лтд. | Новое производное 3-гидрокси-5-арилизотиазола |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
CA2813639A1 (en) | 2010-10-08 | 2012-04-12 | Mochida Pharmaceutical Co. Ltd. | Cyclic amide derivative |
WO2012104206A1 (de) | 2011-02-01 | 2012-08-09 | Boehringer Ingelheim International Gmbh | 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-chinazolin-6- yloxy]-1,4-diaza-spiro[5.5]undecan-5-on dimaleat, dessen verwendung als arzneimittel und dessen herstellung |
NZ617409A (en) | 2011-04-27 | 2015-08-28 | Mochida Pharm Co Ltd | Novel 3-hydroxyisothiazole 1-oxide derivative |
CA2834465A1 (en) | 2011-04-28 | 2012-11-01 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2015524400A (ja) | 2012-07-19 | 2015-08-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 9−[4−(3−クロロ−2−フルオロ−フェニルアミノ)−7−メトキシ−キナゾリン−6−イルオキシ]−1,4−ジアザ−スピロ[5.5]ウンデカン−5−オンのフマル酸塩、その薬物としての使用及び調製 |
IN2015DN03795A (hr) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
SI2920165T1 (sl) | 2012-11-16 | 2017-02-28 | Bristol-Myers Squibb Company | Modulatorji dihidropirazola GPR40 |
KR101569522B1 (ko) | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
DK3107901T3 (da) | 2014-02-19 | 2020-06-22 | Piramal Entpr Ltd | Forbindelser til brug som gpr120 agonister |
US10273230B2 (en) | 2014-07-25 | 2019-04-30 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof |
WO2016038540A1 (en) | 2014-09-11 | 2016-03-17 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
US11186565B2 (en) | 2017-03-31 | 2021-11-30 | Takeda Pharmaceutical Company Limited | Aromatic compound |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
AU2020363377A1 (en) | 2019-10-07 | 2022-04-21 | Kallyope, Inc. | GPR119 agonists |
EP4153589A4 (en) | 2020-05-19 | 2024-06-12 | Kallyope, Inc. | AMPK ACTIVATORS |
WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
CN115181023B (zh) * | 2022-05-17 | 2023-07-28 | 东华理工大学 | 螺环活性增塑剂及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4331179A1 (de) * | 1993-09-14 | 1995-03-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
RU2191007C2 (ru) * | 1996-05-24 | 2002-10-20 | Лиганд Фармасьютикалз Инкорпорейтед | Способ лечения иhcд агонистами rxr |
GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
DE60315776T2 (de) * | 2002-10-14 | 2008-06-05 | Firmenich S.A. | Spiroverbindungen als Duftstoffe |
JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
WO2005051373A1 (ja) * | 2003-11-26 | 2005-06-09 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
JP4074616B2 (ja) | 2003-12-25 | 2008-04-09 | 武田薬品工業株式会社 | 3−(4−ベンジルオキシフェニル)プロパン酸誘導体 |
EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
EP2064193A1 (en) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
EP2684861A3 (en) * | 2007-10-26 | 2014-05-07 | Japan Tobacco Inc. | Spiro compounds and pharmaceutical use thereof |
NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
-
2008
- 2008-10-24 EP EP13184140.5A patent/EP2684861A3/en not_active Withdrawn
- 2008-10-24 DK DK08841970.0T patent/DK2202216T3/da active
- 2008-10-24 RS RS20120400A patent/RS52474B/en unknown
- 2008-10-24 RU RU2010121160/04A patent/RU2490250C2/ru not_active IP Right Cessation
- 2008-10-24 BR BRPI0818687A patent/BRPI0818687A2/pt not_active IP Right Cessation
- 2008-10-24 ES ES08841970T patent/ES2386596T3/es active Active
- 2008-10-24 AU AU2008314933A patent/AU2008314933B2/en not_active Ceased
- 2008-10-24 AR ARP080104642A patent/AR071055A1/es not_active Application Discontinuation
- 2008-10-24 WO PCT/JP2008/069296 patent/WO2009054479A1/ja active Application Filing
- 2008-10-24 TW TW097140805A patent/TWI421070B/zh not_active IP Right Cessation
- 2008-10-24 CN CN2008801132388A patent/CN101835737B/zh not_active Expired - Fee Related
- 2008-10-24 KR KR1020107011427A patent/KR101565622B1/ko not_active IP Right Cessation
- 2008-10-24 PT PT08841970T patent/PT2202216E/pt unknown
- 2008-10-24 ME MEP-2016-195A patent/ME02338B/me unknown
- 2008-10-24 EP EP08841970A patent/EP2202216B1/en active Active
- 2008-10-24 US US12/258,033 patent/US8299296B2/en active Active
- 2008-10-24 PE PE2008001826A patent/PE20091014A1/es not_active Application Discontinuation
- 2008-10-24 MX MX2010004435A patent/MX2010004435A/es active IP Right Grant
- 2008-10-24 MY MYPI2010001866A patent/MY148469A/en unknown
- 2008-10-24 NZ NZ584161A patent/NZ584161A/en not_active IP Right Cessation
- 2008-10-24 PL PL08841970T patent/PL2202216T3/pl unknown
- 2008-10-24 EP EP12173164A patent/EP2508503A1/en not_active Withdrawn
- 2008-10-24 CL CL2008003153A patent/CL2008003153A1/es unknown
- 2008-10-24 CA CA2704013A patent/CA2704013C/en not_active Expired - Fee Related
- 2008-10-24 SI SI200830752T patent/SI2202216T1/sl unknown
- 2008-10-24 JP JP2008273676A patent/JP4568779B2/ja active Active
-
2010
- 2010-03-31 ZA ZA2010/02305A patent/ZA201002305B/en unknown
- 2010-04-22 IL IL205283A patent/IL205283A/en not_active IP Right Cessation
- 2010-05-26 CO CO10062839A patent/CO6321230A2/es active IP Right Grant
- 2010-07-23 JP JP2010165678A patent/JP2010270137A/ja active Pending
- 2010-11-26 HK HK10110999.8A patent/HK1144421A1/xx not_active IP Right Cessation
-
2012
- 2012-08-22 CY CY20121100753T patent/CY1113352T1/el unknown
- 2012-09-04 HR HRP20120696AT patent/HRP20120696T1/hr unknown
- 2012-09-14 US US13/616,389 patent/US20130109710A1/en not_active Abandoned
-
2014
- 2014-08-04 JP JP2014158380A patent/JP2014221829A/ja active Pending
- 2014-11-17 US US14/542,869 patent/US20150299090A1/en not_active Abandoned
-
2016
- 2016-01-06 JP JP2016001396A patent/JP2016102130A/ja not_active Ceased
-
2017
- 2017-03-14 JP JP2017049246A patent/JP2017132787A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120696T1 (hr) | Spiro-prstenasti spoj i njegova medicinska upotreba | |
JP2009120598A5 (hr) | ||
JP2009532453A5 (hr) | ||
WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
MX2009012285A (es) | Inhibidores de diacilglicerol aciltransferasa. | |
WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
RU2009126767A (ru) | Производное 1-фенил-1-тио-d-глюцитола | |
IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
NO20064297L (no) | Aminoalkoholforbindelse | |
RU2012117786A (ru) | Новое производное фенола | |
BRPI0407506A (pt) | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos | |
RU2010119487A (ru) | Пиримидилиндолиновое соединение | |
RU2015138801A (ru) | Способы, соединения и композиции для лечения связанных с ангиотензином заболеваний | |
GB0701366D0 (en) | Novel pharmaceutical compositions | |
EA200970705A1 (ru) | Новые фармацевтические композиции | |
ATE528306T1 (de) | Benzoxazepin-verbindungen, ihre herstellung und verwendung | |
RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
JP2013537240A5 (hr) | ||
JP2015502371A5 (hr) | ||
RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний |